Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:LFCRNASDAQ:NTLANYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.72-7.7%$4.39$3.21▼$8.06$890.03M0.764.45 million shs5.88 million shsLFCRLifecore Biomedical$6.61-3.5%$6.52$3.68▼$7.99$244.74M0.65240,935 shs179,835 shsNTLAIntellia Therapeutics$6.99-6.2%$7.97$5.90▼$28.18$724.05M2.332.69 million shs8.84 million shsRCUSArcus Biosciences$8.98-5.6%$8.25$6.50▼$18.98$950.85M0.88858,923 shs1.38 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-7.69%-6.30%-32.49%-30.60%-43.72%LFCRLifecore Biomedical-3.50%-1.64%-2.22%+13.18%+15.56%NTLAIntellia Therapeutics-6.17%-23.69%-21.20%-30.72%-67.74%RCUSArcus Biosciences-5.52%-0.72%+2.63%-17.51%-40.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.6622 of 5 stars4.53.00.04.42.92.50.6LFCRLifecore Biomedical1.7538 of 5 stars2.32.00.00.01.94.20.6NTLAIntellia Therapeutics4.6147 of 5 stars4.31.00.04.73.22.51.3RCUSArcus Biosciences2.5011 of 5 stars4.51.00.00.01.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$10.39179.27% UpsideLFCRLifecore Biomedical 2.50Moderate Buy$8.0021.03% UpsideNTLAIntellia Therapeutics 2.67Moderate Buy$36.75425.75% UpsideRCUSArcus Biosciences 2.91Moderate Buy$25.67185.82% UpsideCurrent Analyst Ratings BreakdownLatest LFCR, RCUS, ARDX, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $7.005/29/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/21/2025LFCRLifecore BiomedicalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/19/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/12/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $45.005/9/2025NTLAIntellia TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.005/9/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$68.00 ➝ $68.005/9/2025RCUSArcus BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.005/8/2025RCUSArcus BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025RCUSArcus BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$361.71M2.46N/AN/A$0.73 per share5.10LFCRLifecore Biomedical$130.31M1.88N/AN/A$0.37 per share17.86NTLAIntellia Therapeutics$45.57M15.89N/AN/A$11.73 per share0.60RCUSArcus Biosciences$141M6.74N/AN/A$6.17 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A12.00N/A-11.73%-24.87%-10.51%8/7/2025 (Estimated)LFCRLifecore Biomedical$12.01M-$1.45N/AN/AN/A-12.52%-315.23%-12.74%8/15/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.23N/AN/AN/AN/A-49.34%-40.27%8/14/2025 (Estimated)RCUSArcus Biosciences-$307M-$4.19N/AN/AN/A-102.66%-45.59%-22.38%8/14/2025 (Estimated)Latest LFCR, RCUS, ARDX, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million4/3/2025Q3 2025LFCRLifecore Biomedical-$0.14-$0.19-$0.05-$0.47$33.23 million$35.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx0.874.584.31LFCRLifecore Biomedical9.212.321.21NTLAIntellia TherapeuticsN/A6.736.73RCUSArcus Biosciences0.085.245.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%LFCRLifecore Biomedical83.36%NTLAIntellia Therapeutics88.77%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%LFCRLifecore Biomedical32.20%NTLAIntellia Therapeutics3.10%RCUSArcus Biosciences12.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million222.88 millionOptionableLFCRLifecore Biomedical69037.03 million26.58 millionOptionableNTLAIntellia Therapeutics600103.58 million98.59 millionOptionableRCUSArcus Biosciences500105.89 million80.26 millionOptionableLFCR, RCUS, ARDX, and NTLA HeadlinesRecent News About These CompaniesArcus Biosciences (NYSE:RCUS) Stock Price Down 8.6% - Time to Sell?May 31 at 12:48 PM | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 30 at 2:45 AM | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsMay 27, 2025 | businesswire.comArcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Millennium Management LLCMay 25, 2025 | marketbeat.comArcus Biosciences describes new c-Kit inhibitorsMay 24, 2025 | bioworld.comWoodline Partners LP Purchases 45,497 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)May 22, 2025 | marketbeat.comSuvretta Capital Management LLC Has $8.58 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)May 19, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 440,794 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)May 19, 2025 | marketbeat.comAmeriprise Financial Inc. Boosts Stake in Arcus Biosciences, Inc. (NYSE:RCUS)May 17, 2025 | marketbeat.comParkman Healthcare Partners LLC Acquires 248,035 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)May 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)May 16, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Invests $6.93 Million in Arcus Biosciences, Inc. (NYSE:RCUS)May 16, 2025 | marketbeat.comWhy Precision BioSciences, Inc.’s (DTIL) Stock Is Down 9.90%May 15, 2025 | aaii.comCubist Systematic Strategies LLC Grows Position in Arcus Biosciences, Inc. (NYSE:RCUS)May 13, 2025 | marketbeat.comQ2 EPS Estimates for Arcus Biosciences Cut by HC WainwrightMay 11, 2025 | marketbeat.comQ2 Earnings Forecast for Arcus Biosciences Issued By WedbushMay 11, 2025 | marketbeat.comRaymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS)May 11, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Position Increased by Algert Global LLCMay 10, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Shares Gap Down Following Weak EarningsMay 9, 2025 | marketbeat.comWells Fargo & Company Lowers Arcus Biosciences (NYSE:RCUS) Price Target to $26.00May 9, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LPMay 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLFCR, RCUS, ARDX, and NTLA Company DescriptionsArdelyx NASDAQ:ARDX$3.72 -0.31 (-7.69%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.71 -0.01 (-0.27%) As of 05/30/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Lifecore Biomedical NASDAQ:LFCR$6.61 -0.24 (-3.50%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$6.76 +0.15 (+2.27%) As of 05/30/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Intellia Therapeutics NASDAQ:NTLA$6.99 -0.46 (-6.17%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$6.98 -0.01 (-0.09%) As of 05/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Arcus Biosciences NYSE:RCUS$8.98 -0.53 (-5.57%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$9.01 +0.03 (+0.33%) As of 05/30/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
